TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04926545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiao Chai Hu Tang (XCHT)
Description: XCHT 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, except the 1st cycle of chemotherapy for irinotecan used cohort patients.~Additional XCHT, 9g qd will be orally administrated for 4 days during the Round 0 study for irinotecan naive cohort patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiao Chai Hu Tang (XCHT)
Description: XCHT 9g, po qd, 3 days before each cycle of chemotherapy for 5 days, except the 1st cycle of chemotherapy for irinotecan used cohort patients.~Additional XCHT, 9g qd will be orally administrated for 4 days during the Round 0 study for irinotecan naive cohort patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: Raloxifene 60mg po, used as probe for pharmacokinetic testing. For irinotecan naive cohort patients, raloxifene 60mg will be orally administrated on Day 1 and Day 5 (4th day of XCHT administration) during round 0 study, Day 3 (the day before chemotherapy) during round 2 and round 3 study. For irinotecan used cohort patients, raloxifene 60mg will be orally administrated on Day 1 (irinotecan using day) during round 1 study, Day 4 (irinotecan using day) during round 2 study, and Day 3 (the day before chemotherapy) during round 3 study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: Raloxifene 60mg po, used as probe for pharmacokinetic testing. For irinotecan naive cohort patients, raloxifene 60mg will be orally administrated on Day 1 and Day 5 (4th day of XCHT administration) during round 0 study, Day 3 (the day before chemotherapy) during round 2 and round 3 study. For irinotecan used cohort patients, raloxifene 60mg will be orally administrated on Day 1 (irinotecan using day) during round 1 study, Day 4 (irinotecan using day) during round 2 study, and Day 3 (the day before chemotherapy) during round 3 study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen
Description: Patients will receive 3 cycles of FOLFIRI regimen for chemotherapy. Irinotecan intravenous (IV) infusion (180 mg/m2) through a drip into the bloodstream over 90 minutes. Folinic acid (400 mg/m2) IV infusion through a drip into the bloodstream over 2 hours. 5-fluorouracil (5-FU) IV bolus (400 mg/m2) into the bloodstream over 5 minutes, followed by 5-FU (2400 mg/m2) continuous IV infusion through a drip or pump into the bloodstream for 46-48 hours.
Study: NCT06392061

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trilac
Description: Trilac® is a dietary supplement developed by Surveal Pharma to support digestive health and overall well-being. This probiotic contains 4 strains of naturally-occurring bacteria including: Lactobacillus acidophilus, LA-5®, Bifidobacterium animalis, BB-12®, Streptococcus thermophiles, STY-31 and Lactobacillus delbrueckii subsp. Bulgaricus LBY-27 in concentration of 4.5 milliards CFU/capsule. Patients in the probiotic group will be instructed to take one tablet per day for a period of 8 weeks.
Study: NCT04926545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen
Description: Patients will receive 3 cycles of FOLFIRI regimen for chemotherapy. Irinotecan intravenous (IV) infusion (180 mg/m2) through a drip into the bloodstream over 90 minutes. Folinic acid (400 mg/m2) IV infusion through a drip into the bloodstream over 2 hours. 5-fluorouracil (5-FU) IV bolus (400 mg/m2) into the bloodstream over 5 minutes, followed by 5-FU (2400 mg/m2) continuous IV infusion through a drip or pump into the bloodstream for 46-48 hours.
Study: NCT06132672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigators (peer navigator) training
Description: The Navigators training will be designed to increase knowledge and skills to help others (i.e., social network members). Navigators in the intervention group will be trained and supported for 12 months of implementation across years 3 and 4

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: delayed-intervention
Description: Those in the delayed-intervention group will be trained in year 5
Study: NCT04917796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Real and sham acupuncture will be delivered by experienced licensed acupuncturists at MSK. The intervention includes 10 treatments of acupuncture over 8 weeks (i.e., twice per week for two weeks, then one treatment per week for six weeks).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Acupuncture
Description: Real and sham acupuncture will be delivered by experienced licensed acupuncturists at MSK. The intervention includes 10 treatments of acupuncture over 8 weeks (i.e., twice per week for two weeks, then one treatment per week for six weeks).
Study: NCT06241443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hybrid simulation
Description: During the hybrid simulation, a student and a standardized patient participated. The patient wore a wearable pregnancy model. Before the start of the Natural Birth Approach Scenario, a pre-briefing session was conducted. The student's performance during the simulation was recorded on video, and each simulation lasted approximately 30 minutes. After the simulation, a debriefing session was held with the student, and feedback was given. Scales were used to evaluate the implementation of the practices.
Study: NCT05176015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frenzel Lens
Description: pair of magnifying glasses (+20 dioptres) that are worn by the patient and an illuminating system. On using Frenzel goggles, the nystagmus is better seen as a result of eyes being magnified and inhibition of visual fixation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frenzel Lens
Description: pair of magnifying glasses (+20 dioptres) that are worn by the patient and an illuminating system. On using Frenzel goggles, the nystagmus is better seen as a result of eyes being magnified and inhibition of visual fixation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Algorithm
Description: A diagnostic algorithm using the TiTrate approach: continuous, Intermittent, trigger or spontaneous.~The diagnostic algorithm use the REDCap software that include different videos to illustrate diagnostic tests and nystagmus types. Different maneuvers: HINTS+ battery, Dix-Hallpike test, Supine Roll test.~Different Particle Repositioning Techniques will be proposed according to specific tests: Epley and Gufoni maneuvers.~Risk Score is used to assess stroke risk for transient ischaemic attack (TIA): ABCD2 and the Canadian TIA Risk Score

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Algorithm
Description: A diagnostic algorithm using the TiTrate approach: continuous, Intermittent, trigger or spontaneous.~The diagnostic algorithm use the REDCap software that include different videos to illustrate diagnostic tests and nystagmus types. Different maneuvers: HINTS+ battery, Dix-Hallpike test, Supine Roll test.~Different Particle Repositioning Techniques will be proposed according to specific tests: Epley and Gufoni maneuvers.~Risk Score is used to assess stroke risk for transient ischaemic attack (TIA): ABCD2 and the Canadian TIA Risk Score
Study: NCT04908852

Intervention type: OTHER
Intervention: Blood Sample Collection - Observational Study
Description: Blood samples will be collected at enrollment and week 4 and used in analyses to understand associations between metabolic function and symptom experiences.

Intervention type: OTHER
Intervention: Symptom questionnaires - Observational Study
Description: Symptom questionnaires at baseline, 1-, 2-, 3- and 4-weeks.
Study: NCT06560099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: will receive 10 IU oxytocin intravenous bolus over one min and infusion of 10 IU oxytocin in 500 ml of 0.9 saline over four hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: will receive 10 IU oxytocin intravenous bolus over one min and infusion of 10 IU oxytocin in 500 ml of 0.9 saline over four hours.
Study: NCT06083259

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin sponge stabilization with suture and cyanoacrylate
Description: The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, Ethicon, USA)+ supporting sutures (control group)
Study: NCT06241443

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: video-modeling
Description: The students in the group had the opportunity to learn through an educational video that followed the Natural Birth Approach Scenario. Afterward, they put their knowledge into practice and were evaluated using the Birth Approach Clinical Skills Guide. A feedback session followed the practice session. Finally, they were assessed using scales to measure their performance.
Study: NCT06417047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Holding
Description: During the intramuscular injection, the aim is to draw the patients' attention elsewhere by holding their hand.
Study: NCT06098547

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Description: Patients will undergo liver transplantation according to the standard procedures of the institutional Center's protocol (cadaveric or living donor transplantation, whole or partial liver).~Liver transplantation is preceded by an exploratory laparotomy with clinical evaluation and frozen section examination of lymph nodes in the hepatoduodenal ligament and along the common hepatic artery/celiac axis.
Study: NCT05443854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminoglycosides intervention
Description: Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines \[3, 28, 50\].~Systematic aminoglycoside therapy using Amikacin at a dose of 25 to 30 mg/Kg per dose, at a rate of a maximum of 1 infusion per day will be delivered.~Recommended duration will be of three days or until microbiological documentation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lack of protective isolation intervention
Description: Protective isolation will be avoided until ICU discharge is deemed possible. Specific measures regarding nutrition (including avoidance of food consider at risk of fungal contamination) and water protection will be maintained.~Extended universal hygiene measures will be maintained and use of mask will be advocated during viral epidemic periods.~A high degree of compliance as regard to antifungal prophylaxis guidelines and local standard hygiene procedures will be advocated

Intervention type: OTHER
Group type: OTHER
Intervention: No systematic aminoglycosides intervention - standard arm
Description: Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines \[3, 28, 50\].~No systematic aminoglycoside therapy will be provided except in presence of predefined specific organ infection (such intra-vascular infection such endocarditis for example) or drug-resistant infection requiring aminoglycosides.

Intervention type: OTHER
Group type: OTHER
Intervention: Protective isolation intervention - standard arm
Description: Protective isolation will be provided systematically as currently practiced in participating centers. Modality will be in line with recent SRLF guidelines, we will recommend for the patients to receive an isolation the maximal available isolation with the aim to provide:~1. High-efficiency air filtration \[filtration of 99.7% of particles greater than or equal to 0.3 µm; International Organization for Standardization (ISO) class 5 or better\]~2. Geographical isolation in an individual room~3. Technical isolation, including a face mask and a cap. This approach of isolation will however be pragmatic on the basis of the best available level of isolation in line with recommendation, while not delaying ICU admission and patients' care
Study: NCT06449664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADT-train
Description: A new training concept is tested on men with prostate cancer receiving androgen deprivation therapy
Study: NCT06099483

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Action observation and motor imagery
Description: EEG recording was taken while watching a 10-minute video recording of specified breathing exercises and imagining the exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active breathing exercise
Description: EEG recording was taken while the physiotherapist performed active breathing exercises for 10 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: EEG recording was taken while resting with eyes closed for 10 minutes.
Study: NCT06022055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and tissue collection
Description: Blood will be collected for group 1 during (i) the enrolment visit, (ii) in the 24 hours following a seizure, (iii)before the surgery and (iv) in the 36 months following the surgery. The left-over tissue, not useful for diagnostic purpose, will be kept for research.~Blood will be collected for group 2 right before the surgery and in the 36 months following the surgery. The left-over tissue not useful for diagnostic purpose will be kept for research.
Study: NCT05967130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Phage
Description: Inserting specific specimen of phages in to the bladder
Study: NCT06083259

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin sponge stabilization with cyanoacrylate
Description: Seconder The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, USA) (test group)
Study: NCT06558981

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Ppatients would receive external radiation therapy within 6 weeks after surgery, using intensity-modulated radiation therapy (IMRT) or volume modulated radiation therapy (VMAT) techniques. RAI would be administered as standard care. The treatment window is within 6 months after surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: radioiodine treatment
Description: RAI would be delivered based on the condition of residual lesions after surgery. The treatment window is within 6 months after surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: radioiodine treatment
Description: RAI would be delivered based on the condition of residual lesions after surgery. The treatment window is within 6 months after surgery.
Study: NCT06560749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Measure the impact of physical exercise in the cognition of pacients diagnosed with Bipolar Disorder
Study: NCT06562322

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be received placebo PBMT on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 300 J
Description: Participants will be received PBMT at 300 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 600 J
Description: Participants will be received PBMT at 600 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1260 J
Description: Participants will be received PBMT at 1260 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
Study: NCT06561867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90 MG
Description: Efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 100 MG
Description: Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study: NCT04738448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Therapy Group
Description: The art therapy intervention will be executed by the same Medical University of South Carolina (MUSC) board-certified art therapist for each group. The art therapist is a masters-level, licensed practitioner who has experience working in the healthcare system and treating providers. The same art therapy practices that are utilized in daily practice at MUSC will be employed in this study, with a focus on reducing burnout symptoms. Pilot testing of the intervention has been performed informally at MUSC with positive feedback reported by healthcare providers.
Study: NCT06560086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: A fetal developmental stage is precisely determined. Then, fetal tissues are extracted for in vitro cultivation. Intact aborted fetal testicular tissues are cultured in a medium containing 10-6 mol/L ketoconazole, which is the injectable solution powder. Ketoconazole is administered starting on the first day and then every other day, for a total of 7 times over the 14-day in vitro culture period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing Hormone
Description: A fetal developmental stage is precisely determined. Then, fetal tissues are extracted for in vitro cultivation. Intact aborted fetal testicular tissues are cultured in a medium containing 1 IU/mL luteinizing hormone, which is the injectable solution powder. Luteinizing hormone is administered starting on the first day and then every other day, for a total of 7 times over the 14-day in vitro culture period.
Study: NCT05175365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance
Description: Each session consists of a 60-minute dance class taught by a professional dancer. Dance classes begin with a seated warm-up with various coordination, rhythm, range of motion, memorization and coordination exercises. The level of difficulty of the exercises increases as the sessions progress. Balance is also an important part of training as well as the feeling of being part of a group, of interacting with each other. The hour ends with stretching in a sitting position.
Study: NCT05312112

Intervention type: DRUG
Intervention: Venetoclax
Description: Observational study of venetoclax in AML

Intervention type: DRUG
Intervention: Gilteritinib
Description: Observational study of gilteritinib in AML
Study: NCT04970108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Egito
Description: EGITO Egito coated tablet. EMPAGLIFLOZIN PLACEBO Empagliflozin placebo coated tablet. TELMISARTAN PLACEBO Telmisartan coated tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin + telmisartan
Description: Drug: EMPAGLIFLOZIN Empagliflozin 25 mg coated tablet. Drug: TELMISARTAN Telmisartan 40/80 mg coated tablet. EGITO PLACEBO Egito placebo coated tablet.
Study: NCT00411658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryopreserved
Study: NCT06551493

Intervention type: OTHER
Intervention: Observation of postnatal wound assessment
Description: Observation of postnatal wound assessment

Intervention type: OTHER
Intervention: Observation of postnatal wound assessment
Description: Observation of postnatal wound assessment

Intervention type: OTHER
Intervention: Interview
Description: Interview to elicit individual perspectives of wound assessment

Intervention type: OTHER
Intervention: Interview
Description: Interview to elicit individual perspectives of wound assessment
Study: NCT06260293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: A total of 4 exercise interventions.~Twice In-patient exercise interventions: exercises on the ward at POD1, and POD2, and Recommended walking and stretching.~Twice home-based exercise interventions: post-discharge, Recommended 30 minutes of low to moderate-intensity walking and daily bodyweight exercises per day(150 minutes each week). and remote exercises 1 per week.
Study: NCT06117137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Group empagliflozin: stander treatment of type two diabetes mellitus plus empagliflozin~Group dapa:standard treatment of type 2 Diabetes mellitus and dapagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Group empagliflozin: stander treatment of type two diabetes mellitus plus empagliflozin~Group dapa:standard treatment of type 2 Diabetes mellitus and dapagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Group empagliflozin: stander treatment of type two diabetes mellitus plus empagliflozin~Group dapa:standard treatment of type 2 Diabetes mellitus and dapagliflozin
Study: NCT06050772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality Reminiscence
Description: a computer-generated environment using head-mounted displays (HMDs) that provide a fully immersive, completely engaging, and realistic experience so that users feel like they are a part of the virtual world

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Reminiscence Therapy
Description: RT is a technique that encourages older adults' positive emotions and coping mechanisms by using the recall of earlier memories and the sharing of life experiences.
Study: NCT05759312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab 240mg IV every 2 weeks
Study: NCT05994183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: Dexamethasone 0.6 mg/kg/dose orally (max 16 mg/dose)
Study: NCT05759312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Metformin 2000mg PO QD
Study: NCT05800366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: human IgG1-bispecific antibody, via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab
Description: an antibody drug conjugate (ADC) that contains a humanized IgG1 anti-human CD79b monoclonal antibody, via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Per standard care, via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Per standard care, via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Per standard care, via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Per standard care, orally